FGL Peptide vs P21
Both compounds occupy the cognitive-plasticity research space but from distinct receptor-signalling angles. FGL peptide is the NCAM-derived FGFR-agonist research compound with the distinctive history of reaching Phase II clinical trial in Alzheimer's disease before its clinical-development trajectory was wound down. P21 is a CNTF-derived hexapeptide targeting adult hippocampal neurogenesis through JAK-STAT signalling.
At a glance
| FGL Peptide | P21 | |
|---|---|---|
| Structural class | NCAM-derived 15-amino-acid peptide | CNTF-derived hexapeptide |
| Primary receptor engagement | FGFR (fibroblast growth factor receptor) | LIF/CNTF receptor / JAK-STAT axis |
| Signature cognitive-plasticity mechanism | FGFR signalling → synaptic plasticity, neurogenesis | JAK-STAT signalling → adult hippocampal neurogenesis |
| Human clinical trial history | Alzheimer's disease Phase II completed (null primary endpoint) | None — preclinical only |
| Route of administration | Parenteral (intraperitoneal or intranasal in research) | Subcutaneous / intraperitoneal |
| Evidence tier | C | C |
| Signature research application | Alzheimer's disease cognitive-endpoint research (historical) | Cognitive-ageing hippocampal neurogenesis research |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
Receptor-signalling angle
FGFR versus JAK-STAT — different research-tool positioning
FGL peptide is a research tool for probing FGFR (fibroblast growth factor receptor) engagement in cognitive-plasticity contexts. FGFR signalling contributes to synaptic plasticity, adult neurogenesis, and neuronal-survival pathways relevant to cognitive function and cognitive decline. FGL's derivation from the NCAM (neural cell adhesion molecule) second fibronectin type-III domain provides the specific structural basis for its FGFR-agonist activity.
P21 is a research tool for probing LIF/CNTF-receptor and downstream JAK-STAT signalling in cognitive-plasticity contexts. Its distinctive mechanism-of-action is JAK-STAT-mediated adult hippocampal neurogenesis — new neuron addition to the dentate gyrus of the hippocampus in aged animal models. Its cognitive-endpoint effects in Alzheimer's-model transgenic mice have been characterised.
The two receptor-signalling angles are distinct but not mutually exclusive. Research designs that need to probe multiple cognitive-plasticity mechanisms could plausibly draw on both compounds; research designs that need to isolate specific receptor-signalling contributions to cognitive-endpoint effects would select the more specific tool.
Clinical-development history
Phase II history versus preclinical-only trajectory
FGL peptide has a distinctive clinical-development history in that it reached Phase II clinical trial in mild-to-moderate Alzheimer's disease before the clinical-development trajectory was wound down. The Phase II experience is instructive for the peptide-based cognitive-relevance research field — a mechanistically-well-characterised research compound with strong preclinical rationale reached Phase II and failed to demonstrate clinical efficacy at that stage, providing a real caution against extrapolating from preclinical mechanism-strength to clinical-efficacy prediction.
P21 has not reached clinical-development stage — the evidence base remains preclinical, though the preclinical characterisation of adult hippocampal neurogenesis and cognitive-endpoint effects in Alzheimer's-model transgenic mice provides substantial mechanism-of-action support.
For research-tool selection the clinical-development history difference is more informative than the current evidence-base tier suggests. FGL's Phase II experience provides real clinical-context data-points that P21 lacks; but FGL's negative Phase II primary endpoint also constrains the strength of clinical-application claims. P21's preclinical-only status means clinical-application claims are speculative rather than negative.